Targovax presents ONCOS-102 scientific rationale at the European Society of Gene and Cell Therapy
Studies to date have shown the ability of ONCOS-102 to immune activate patients with treatment refractory malignant mesothelioma at lesional level Oslo, 21th October, 2016: Targovax, a clinical stage company focused on developing and commercializing novel immuno-oncology combination therapies, has today presented the scientific rationale for the clinical development of ONCOS-102 in the treatment of malignant mesothelioma at the European Society of Gene and Cell Therapy 2016 in Florence, Italy. Lukasz Kuryk, Senior Research Scientist with Targovax, will review in-vitro, in-vivo and